Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBITDA MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) EBITDA Margin (2022 - 2024)

Summit Therapeutics (SMMT) has disclosed EBITDA Margin for 1 consecutive years, with 679777.78% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, EBITDA Margin changed N/A year-over-year to 679777.78%, compared with a TTM value of 10244644.44% through Sep 2025, up 1024148417.0%, and an annual FY2022 reading of 11131.63%, down 632207.0% over the prior year.
  • EBITDA Margin was 679777.78% for Q4 2024 at Summit Therapeutics, up from 1945.04% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 679777.78% in Q4 2024 and bottomed at 1392.95% in Q1 2024.